April 2019: Promotion of an unlicensed medicine by Aclardian Limited
Updated 24 May 2019
© Crown copyright 2019
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-april-2019/april-2019-promotion-of-an-unlicensed-medicine-by-aclardian-limited
The MHRA became aware of a brochure available at an Aclardian trade stand at the Neonatal & Paediatric Pharmacists Group conference in November 2018 that provided information on a branded unlicensed medicine, available as a ‘special’.
Aclardian provided assurances that the material was not freely available at the stand, and was provided only in response to specific and unsolicited requests from registered customers or healthcare professionals.
However, the MHRA considered that the brochure contained detailed claims about the benefits of the product that went beyond that required for factual responses to unsolicited questions. Aclardian withdrew the brochure and said that they would ensure that material made available in response to future unsolicited requests is of a non-promotional nature and is limited to that required to answer the specific question asked.